Saxony has established itself as a dynamic life-sciences hub and provides an attractive environment for investors and start-ups The SaxoCell’ network and CMI major research centre are furthering innovations in cell and gene therapy Interdisciplinary co-operation offers huge growth opportunities for applications such as point-of-care diagnostics Leipzig as host of BIO-Europe 2022
Precirix NV raises €80m in Series B financing
Latest NewsWith €80m from a Series B financing in its pocket, Belgian Precirix NV plans to advance its pipeline of precision radiopharmaceuticals.
Sanofi bags €300m from US investor Blackstone
Latest NewsSanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma.
Life-sciences hub Saxony: a driver of innovation for cell and gene therapy
Sponsored PublicationsSaxony has established itself as a dynamic life-sciences hub and provides an attractive environment for investors and start-ups The SaxoCell’ network and CMI major research centre are furthering innovations in cell and gene therapy Interdisciplinary co-operation offers huge growth opportunities for applications such as point-of-care diagnostics Leipzig as host of BIO-Europe 2022
Join 900 US CEOs protest against Ukraine invasion
Latest NewsUS Life Science leaders pledge to economically disengage from Russia.
Join 900 US CEOs protest against Ukraine war
OpinionUS Life Science leaders pledge to economically disengage from Russia.
Scenic Biotech BV announces $31m financing
Latest NewsScenic Biotech BV will use an incoming $31m (€28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease.
·
Kurma Partners closes growth fund at €160m
Latest NewsFrench venture capital expert Kurma Partners has closed its Growth Opportunities Fund at €160m and targets a final closing at €250m.
mRNA for Africa
Latest NewsModerna will build its first mRNA production facility in Kenya, investing up to US$500m.
PhoreMost with new CEO
AppointmentsSince the beginning of March, Dr Neil Torbett has been the new Chief Executive Officer of Cambridge-based PhoreMost Ltd.
Epsilogen raise £30.75m in Series B financing
Latest NewsIgE cancer antibody specialist Epsilogen Ltd has closed a £30.75m round led by Novartis Venture Fund to advance Phase Ib studies with MOv18 IgE in platinum-resistant ovarian cancer.